2025-06-05-Jefferies-VTYX_ALGS_ALXO_IMRX_-杰富瑞医疗会议第二天的CEO炉边谈话_9页_108kb

Report Summary: Jefferies Global Healthcare Conference - CEO Firesides Analysis

Event: Jefferies HC Conference Day 2 (NYC, June 5, 2025)
Companies Analyzed: VTYX, ALGS, ALXO, IMRX

Key Highlights:

• VTYX:

  • Focus: NLRP3 Inhibitor (VTX3232) for CNS Penetration.
  • Upcoming Data: Phase II top-line data for Parkinson's (June) and Obesity (H1/26). Parkinson's study (28 days, early patients) assesses safety (TRE, PK/PD, biomarkers, short-term inflammation). Obesity study (3 months, ~40 pts/arm) powered for weight loss, seeks >30% improvement vs semaglutide (low expectations).
  • Mechanism: Novel mechanism for cardiometabolic disease differentiated by evaluating secondary endpoints across multiple systems.
  • Valuation/Risk: Recent trade-up linked to a potential SNY/VRTX partnership (ROFN pending obesity data).
  • Rating: VTYX ($2.25) - BUY.

• ALGS:

  • Focus: Oral CAM HBV therapy, MASH drug (Fibrotics).
  • Upcoming Data: Phase II initiation mid-year, topline HBV DNA suppression data expected 2026 (interim EAg at W24, EAg- at W12), full data 2027.
  • Biomarker Opportunity: Addresses chronic suppression need in a large (30% of patients) HBsAg low population subsegment.
  • Mechanism: Potent prodrug with high cellular delivery vs earlier (less potent, lower bioavail) generations. Designed for high potency (100x Rezdiffra) and better tolerability (no CYP liability, no skin tx).
  • Valuation/Risk: Potential backbone for HBV suppression. Ongoing BD discussions, particularly for MASH.
  • Rating: ALGS ($6.05) - BUY.

• ALXO:

  • Focus: EGFR ADC (VTX-2102).
  • Upcoming Data: Phase I initiation Q3 2025 (Cleaner safety profile vs earlier ADCs expected). Phase II combo studies in breast & CRC (with trastuzumab/cetuximab) imminent.
  • Mechanism: Optimized EGFR antibody reduces off-target toxicity (avoids skin tx), targets EGFR-expressing solid tumors.
  • Valuation/Risk: High probability of working if safety looks good. Needs sufficient cash to fund upcoming catalyst data. Scenarios: cash overhang, financing option open.
  • Rating: ALXO ($0.53) - BUY.

• IMRX:

  • Focus: MEK Inhibitor (GDC-0973).
  • Upcoming Data: Phase IIa top-line PFS data in pancreatic cancer (Q2 2025), survival data from ~30pts expected. Initial response rate (43%) is favorable vs chemo.
  • Mechanism: Unique PK profile allows cyclic inhibition in combination with chemo without additive toxicity. Targets PFS improvement vs chemotherapeutics (23-32% response).
  • Valuation/Risk: Seeking Phase III study (randomized vs chemo alone, PFS/OS primary endpoints) if Phase IIa is encouraging. ~$36M cash, runway to 2026. Potential for future NSCLC/melanoma combos.
  • Rating: IMRX ($2.05) - HOLD.

Additional Market Mentions (on given ratings): ALX Oncology (ALXO: $0.53, BUY), Sanofi (SNY: $49.76, BUY), Regeneron (REGN: $483.07, BUY), Vigil Neuroscience (VIGL: $7.88, HOLD).

**(Note: All ticker symbols, share prices, and ratings are valid as of the report date/time/Jun 5, 2025 18:42 P.M.)**